Literature DB >> 8799550

Antagonism of striatal muscarinic receptors inhibiting dopamine D1 receptor-stimulated adenylyl cyclase activity by cholinoceptor antagonist used to treat Parkinson's disease.

M C Olianas1, P Onali.   

Abstract

A number of cholinoceptor antagonists used in the treatment of Parkinson's disease were examined for their ability to antagonize either the muscarinic receptor-mediated inhibition of dopamine D1 receptor-stimulated adenylyl cyclase or the muscarinic receptor-mediated stimulation of [3H]-inositol phosphates ([3H]-IPs) formation in rat striatal membranes. The drugs were found to block the receptors inhibiting adenylyl cyclase activation with high affinity and more potently than those stimulating [3H]-IPs formation. Moreover, their rank order of potencies for the former effect showed good correlation with their clinical efficacies. These data suggest that the blockade of the muscarinic receptor-mediated inhibition of striatal dopamine D1 receptor activation may be one of the mechanisms by which cholinoceptor blocking drugs exert their antiparkinsonian effect.

Entities:  

Mesh：

Substances：

Year:  1996        PMID： 8799550      PMCID： PMC1909524          DOI： 10.1111/j.1476-5381.1996.tb15474.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN： 0007-1188            Impact factor:   8.739


  6 in total

1.  Specific inhibition of dopamine D-1-mediated cyclic AMP formation by dopamine D-2, muscarinic cholinergic, and opiate receptor stimulation in rat striatal slices.

Authors:  E Kelly; S R Nahorski
Journal:  J Neurochem       Date:  1986-11       Impact factor: 5.372

2.  Muscarinic receptors modulate dopamine-activated adenylate cyclase of rat striatum.

Authors:  M C Olianas; P Onali; N H Neff; E Costa
Journal:  J Neurochem       Date:  1983-11       Impact factor: 5.372

3.  Antagonism by antimuscarinic and neuroleptic compounds at the five cloned human muscarinic cholinergic receptors expressed in Chinese hamster ovary cells.

Authors:  C Bolden; B Cusack; E Richelson
Journal:  J Pharmacol Exp Ther       Date:  1992-02       Impact factor: 4.030

4.  Concerted CMP-dependent [3H]inositol labeling of phosphoinositides and agonist activation of phospholipase C in rat brain cortical membranes.

Authors:  E Claro; M A Wallace; J N Fain
Journal:  J Neurochem       Date:  1992-06       Impact factor: 5.372

5.  Chronic blockade of muscarinic cholinergic receptors by systemic trihexyphenidyl (Artane) administration modulates but does not mediate the dopaminergic regulation of striatal prepropeptide messenger RNA expression.

Authors:  M Mavridis; M Rogard; M J Besson
Journal:  Neuroscience       Date:  1995-05       Impact factor: 3.590

6.  Differential effect of selective D-1 and D-2 dopamine receptor agonists on levodopa-induced dyskinesia in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine- exposed monkeys.

Authors:  P Blanchet; P J Bédard; D R Britton; J W Kebabian
Journal:  J Pharmacol Exp Ther       Date:  1993-10       Impact factor: 4.030
  6 in total
  3 in total

1.  Enhancement of D1 dopamine receptor-mediated locomotor stimulation in M(4) muscarinic acetylcholine receptor knockout mice.

Authors:  J Gomeza; L Zhang; E Kostenis; C Felder; F Bymaster; J Brodkin; H Shannon; B Xia; C Deng; J Wess
Journal:  Proc Natl Acad Sci U S A       Date:  1999-08-31       Impact factor: 11.205

2.  Sensing Positive versus Negative Reward Signals through Adenylyl Cyclase-Coupled GPCRs in Direct and Indirect Pathway Striatal Medium Spiny Neurons.

Authors:  Anu G Nair; Omar Gutierrez-Arenas; Olivia Eriksson; Pierre Vincent; Jeanette Hellgren Kotaleski
Journal:  J Neurosci       Date:  2015-10-14       Impact factor: 6.167

3.  Cholinergic connectivity: it's implications for psychiatric disorders.

Authors:  Elizabeth Scarr; Andrew S Gibbons; Jaclyn Neo; Madhara Udawela; Brian Dean
Journal:  Front Cell Neurosci       Date:  2013-05-03       Impact factor: 5.505
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.